Tekla Capital Management LLC grew its holdings in Protagonist Therapeutics Inc (NASDAQ:PTGX) by 958.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 82,822 shares of the company’s stock after acquiring an additional 75,000 shares during the quarter. Tekla Capital Management LLC’s holdings in Protagonist Therapeutics were worth $1,723,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Farallon Capital Management LLC acquired a new stake in Protagonist Therapeutics in the fourth quarter worth about $18,720,000. BlackRock Inc. boosted its holdings in Protagonist Therapeutics by 10.5% in the fourth quarter. BlackRock Inc. now owns 494,528 shares of the company’s stock worth $10,286,000 after acquiring an additional 47,003 shares in the last quarter. First Manhattan Co. raised its stake in shares of Protagonist Therapeutics by 2,408.2% in the fourth quarter. First Manhattan Co. now owns 416,364 shares of the company’s stock worth $8,660,000 after purchasing an additional 399,764 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Protagonist Therapeutics by 3.8% in the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock worth $3,680,000 after purchasing an additional 11,881 shares during the last quarter. Finally, AWM Investment Company Inc. purchased a new position in shares of Protagonist Therapeutics in the fourth quarter worth about $3,686,000. 57.77% of the stock is owned by institutional investors and hedge funds.
Protagonist Therapeutics Inc (NASDAQ:PTGX) opened at $23.08 on Friday. Protagonist Therapeutics Inc has a 12 month low of $8.00 and a 12 month high of $23.97.
Several research analysts have recently issued reports on the company. BMO Capital Markets restated an “outperform” rating and issued a $42.00 price objective (down from $44.00) on shares of Protagonist Therapeutics in a research note on Thursday. BidaskClub upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 3rd. Zacks Investment Research cut Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 4th. Finally, Stifel Nicolaus assumed coverage on Protagonist Therapeutics in a research note on Monday, January 29th. They issued a “buy” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $32.25.
In related news, insider Dinesh V. Ph D. Patel sold 1,790 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $19.55, for a total transaction of $34,994.50. Following the completion of the transaction, the insider now directly owns 192,227 shares in the company, valued at $3,758,037.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas P. O’neil sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $20.00, for a total value of $160,000.00. Following the transaction, the chief financial officer now owns 4,000 shares of the company’s stock, valued at $80,000. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,944 shares of company stock valued at $319,839. Company insiders own 15.50% of the company’s stock.
Protagonist Therapeutics Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics Inc (NASDAQ:PTGX).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.